← All trials
NCT04443270
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2020
- Primary completion
- Oct 31, 2020
- Completion date
- Jan 31, 2021
- First posted
- Jun 23, 2020
- Last posted
- Jul 14, 2020
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CMN "20 de Noviembre"Lead sponsor
- CMN "20 de Noviembre"Reponsible party - principal investigator
- CMN "20 de Noviembre"Overall official - principal investigator
- CMN "20 de Noviembre"Study director
- CMN "20 de Noviembre"Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.